Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has boosted its coffers by A$1.6 million after receiving a refund under the Australian Government’s Research and Development (R&D) Tax Incentive Scheme.
This R&D claim covers the company’s R&D expenditure on its structural heart technologies for the year ended December 31, 2021.
The Australian Government’s R&D Tax Incentive encourages companies to engage in R&D, by providing a refundable tax offset for eligible R&D activities, thereby assisting businesses to recover some of their costs related to R&D.
Committed to R&D
This refund confirms the company’s significant and ongoing commitment to invest in, research and develop its ADAPT® technology and product development pipeline including Anteris’ DurAVRTM, Transcatheter Heart Valve System.
The company plans to use these funds for further research and development activities.
About Anteris
Anteris is a structural heart company that delivers clinically superior and durable solutions through better science and better design.
Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.
Anteris’ DurAVRTM 3D single-piece aortic heart valve replacement addresses the needs of younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.
The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of the DurAVRTM 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors.